Endpoints NewsRedosable Gene-Therapy Developer Generation Bio Wins $100M Series B FinancingGenetic Engineering & Biotechnology NewsGeneration Bio, a developer of redosable gene therapies, said today it has closed on a $100 million Series B financing, w… Continue reading
The Pharma LetterCell and Gene Therapy Catapult enters Japanese collaborationThe Pharma LetterThe UK government-backed Cell and Gene Therapy Catapult (CGT Catapult) today announced it has signed a Memorandum of Understanding (MoU) with the Japanese Soc… Continue reading
GlobeNewswire (press release)Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 …GlobeNewswire (press release)CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) — Intellia Therapeutics, … Continue reading
OncLive |
Hepatocellular Carcinoma: Future Role of Immunotherapy
OncLive Ghassan Abou-Alfa, MD: While we’re getting all those great results from checkpoint inhibitors, as we just discussed, you already have nivolumab onboard, you have pembrolizumab onboard, and you have durvalumab and tremelimumab in combination onboard … |
physicsworld.com |
Biofabrication
physicsworld.com Two years on from Groll and colleagues’ reappraisal, biofabrication can be found describing the generation of nanostructured assemblies containing biological materials. And updating the picture further, subsets of the broader field also include uses in … |